by Plus Therapeutics | Jun 27, 2024 | LM
❗NEW CLINICAL TRIAL INVESTIGATION SITE❗ We are pleased to announce the addition of Ohio State University in Columbus, Ohio to our ReSPECT-LM Clinical Trial with Principal Investigator Shirley Ong M.D.. This site is NOW ENROLLING patients. Learn More about Dr. Ong:...
by Plus Therapeutics | Jun 19, 2024 | LM
June is Brain & Spine Metastasis Awareness Month! 🧠🎗️ We want to continue to raise awareness for Leptomeningeal Metastases, which is diagnosed in approximately 110,000 cases per year in the U.S. Learn more about this metastatic cancer by visiting our Comprehensive...
by Plus Therapeutics | Jun 18, 2024 | Uncategorized
Plus Therapeutics presented data on its novel radioisotope rhenium-186 at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in Toronto. Link to presentation: https://bit.ly/4bd9GyB An oral presentation titled, “Radiation Absorbed...
by Plus Therapeutics | Jun 13, 2024 | Uncategorized
We are excited to have Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center join us as Vice President of Medical Affairs and Medical Director. Dr. Fuller will help lead the...
by Plus Therapeutics | Jun 12, 2024 | GBM
📣 ReSPECT-GBM Clinical Trial is now a @the_abta Featured Clinical Study Check it out here: https://bit.ly/45iB7WE The American Brain Tumor Association’s (ABTA) Featured Clinical Trial Program is part of their ongoing efforts to educate and support patients with brain...
Recent Comments